Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Matthias Leisegang"'
Autor:
Zsofia Foldvari, Cathrine Knetter, Weiwen Yang, Thea Johanne Gjerdingen, Ravi Chand Bollineni, Trung The Tran, Fridtjof Lund-Johansen, Arne Kolstad, Kimberley Drousch, Robert Klopfleisch, Matthias Leisegang, Johanna Olweus
Publikováno v:
npj Vaccines, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Cancer immunotherapy using T cell receptor-engineered T cells (TCR-Ts) represents a promising treatment option. However, technologies for pre-clinical safety assessment are incomplete or inaccessible to most laboratories. Here, TCR-T off-tar
Externí odkaz:
https://doaj.org/article/5e4ddbe304be4fdbbf81618f711ffbcd
Autor:
Matthias Leisegang, Thomas Blankenstein, Vivian Scheuplein, Elisa Kieback, Matthias Obenaus, Ioannis Gavvovidis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5764ca011aa54c308996bdffb02e1ba6
Autor:
Teng Wei, Matthias Leisegang, Ming Xia, Kazuma Kiyotani, Ning Li, Chenquan Zeng, Chunyan Deng, Jinxing Jiang, Makiko Harada, Nishant Agrawal, Liangping Li, Hui Qi, Yusuke Nakamura, Lili Ren
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Adoptive cell therapy using TCR-engineered T cells (TCR-T cells) represents a promising strategy for treating relapsed and metastatic cancers. We previously established methods to identify neoantigen-specific TCRs based on patients’ PBMCs. However,
Externí odkaz:
https://doaj.org/article/9e9f7a88248645ad8a608d5930057a2a
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 2, Pp n/a-n/a (2020)
Tumor necrosis factor (TNF) was discovered in 1975 as a lipopolysaccharide‐induced serum factor that causes necrosis of tumors (Carswell et al, 1975). It was later found that TNF and cachectin, a factor causing wasting disease, were one and the sam
Externí odkaz:
https://doaj.org/article/70625ecba80547a0a0f8ea35aab06d45
Autor:
Lili Ren, Matthias Leisegang, Boya Deng, Tatsuo Matsuda, Kazuma Kiyotani, Taigo Kato, Makiko Harada, Jae-Hyun Park, Vassiliki Saloura, Tanguy Seiwert, Everett Vokes, Nishant Agrawal, Yusuke Nakamura
Publikováno v:
OncoImmunology, Vol 8, Iss 4 (2019)
To develop a practically applicable method for T-cell receptor (TCR)-engineered T cell immunotherapy targeting neoantigens, we have been attempting to identify neoantigen-specific T cell receptors (TCRs) and establish TCR-engineered T cells in a 3–
Externí odkaz:
https://doaj.org/article/15eb1b9017694b209f9bc758b96dd2d5
Publikováno v:
Molecular Immunology. 154:61-68
The therapy of cancer by adoptive T cell transfer (ACT) requires T cell receptors (TCRs) with optimal affinity for HLA class I-bound peptides (pHLA-I). But not every patient responds to ACT. Therefore, it is critical to understand the individual fact
Autor:
Matthias Leisegang, Hans Schreiber, Thomas Kammertoens, Eric G. Pamer, Eric R. Littmann, Madeline Steiner, Kazuma Kiyotani, Steven P. Wolf, Theodore G. Karrison, Karin Schreiber
Burnet postulated that the diversity of T-cell receptors (TCR) allows T cells to protect against the development of cancers that display antigens with a similar, seemingly endless diversity. To test this hypothesis, we developed a strategy in which a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53fe49a09de6d67f5c995cc3679372d8
https://doi.org/10.1158/2326-6066.c.6550185.v1
https://doi.org/10.1158/2326-6066.c.6550185.v1
Autor:
Matthias Leisegang, Hans Schreiber, Thomas Kammertoens, Eric G. Pamer, Eric R. Littmann, Madeline Steiner, Kazuma Kiyotani, Steven P. Wolf, Theodore G. Karrison, Karin Schreiber
Supplementary information containing Supplementary Methods, Supplementary References, Supplementary Figure 1, and Supplementary Figure 2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a90c35520e90bff40dd1c161783f262e
https://doi.org/10.1158/2326-6066.22543239
https://doi.org/10.1158/2326-6066.22543239
Autor:
Elfriede Noessner, Wolfgang Uckert, Dolores J. Schendel, Thomas Blankenstein, Boris Engels, Adriana Turqueti-Neves, Matthias Leisegang
Purpose: Adoptive therapy with genetically engineered T cells carrying redirected antigen specificity is a new option for the treatment of cancer. This approach is not yet available for metastatic renal cell carcinoma (RCC), due to the scarcity of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f760b6c981c7a93014f6cd17f5cf13
https://doi.org/10.1158/1078-0432.c.6519209.v1
https://doi.org/10.1158/1078-0432.c.6519209.v1
Autor:
Thomas Blankenstein, Paul Nghiem, Natalie Miller, Gerald Willimsky, Matthias Leisegang, Ioannis Gavvovidis
MHC-I expression in re-isolated MC703-KLL tumor cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d7e26f8df167ad07819d48965630bdd
https://doi.org/10.1158/1078-0432.22464711.v1
https://doi.org/10.1158/1078-0432.22464711.v1